Wayne Macfadden MD evaluates patients for medication-assisted treatment for substance use disorders. Medication-assisted treatment is an evidence-based approach using medications like buprenorphine and naltrexone. When assessing eligibility, Dr. Macfadden considers factors such as a history of chronic relapse, addiction originating from prescribed opioids, and being in the early stages of treatment where cravings are more severe.

1. Determining Eligibility for
Medication-Assisted Treatment
By: Wayne Macfadden MD

2. Determining Eligibility for Medication-Assisted
Treatment
In addition to operating International Psychiatric Services
(https://www.internationalpsychiatricservices.com) with his wife, Wayne Macfadden MD evaluates
and develops treatment plans for patients with substance use disorders. Wayne Macfadden MD is
experienced in incorporating medications, such as buprenorphine and naltrexone, into anti-
addiction treatment protocols.

3. Determining Eligibility for Medication-Assisted
Treatment
Medication-assisted treatment (MAT) is an evidence-based approach to the treatment of opioid
and alcohol addictions. While MAT is effective, not every patient is a candidate for the treatment.
When assessing people with substance use disorders, psychiatrists may consider the following to
determine if MAT is appropriate:

4. Determining Eligibility for Medication-Assisted
Treatment
- Chronic relapse: MAT is often considered for patients who have experienced several relapses.
This may be due to exceptionally strong physical cravings, extreme withdrawal symptoms, or
underlying physical or mental health issues.

5. Determining Eligibility for Medication-Assisted
Treatment
- Addiction origin: While MAT can assist most eligible patients during recovery, it is the preferred
choice for patients who developed an opioid use disorder after they were prescribed opioid pain
relievers. These patients are less likely to have tried other addictive drugs.

6. Determining Eligibility for Medication-Assisted
Treatment
- Treatment stage: Patients in the early stages of treatment often experience more severe
cravings. Starting recovery with MAT can reduce physical symptoms and allow patients to focus on
their psychological health, and better develop relapse prevention strategies.